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We describe a case of blastomycosis in an 8-year-old
boy with Blastomyces-associated osteomyelitis and possi-
ble pulmonary involvement. We also identify 309 cases of
blastomycosis in Ontario that were seen during a 10-year
period, 57% of which occurred from 2001 to 2003. The
overall incidence during the study period was 0.30 cases
per 100,000 population. Most patients were from north
Ontario (n = 188), where the incidence was 2.44 cases per
100,000. The incidence in the Toronto region was 0.29 per
100,000. Thirteen percent of cases occurred in children
<19 years of age. These findings substantially increase the
number of known cases in Ontario and Canada. Clinicians
may encounter persons infected with Blastomyces dermati-
tidis and must be familiar with its signs and symptoms and
be aware of locations, such as northwestern Ontario, where
disease is endemic or hyperendemic. We advocate resum-
ing blastomycosis as a reportable disease in Ontario to
facilitate tracking cases.
F
irst described by Gilchrist in 1894 (1), blastomycosis
has been documented in Canada since at least 1910 (2).
The incidence and epidemiologic features of the disease
are poorly understood because of underrecognition, diffi-
culty in isolating Blastomyces dermatitidis from natural
sites, lack of an effective skin test, and because blastomy-
cosis is not nationally reportable in either Canada or the
United States (3). Blastomycotic infections in Canada have
recently been reported in international (4) and Canadian
(5–7) literature. We report a case of pediatric blastomy-
cotic osteomyelitis and the results of an almost 10-year
review of Blastomyces infection in Ontario through reports
of laboratory isolates submitted to the Central Public
Health Laboratory (CPHL), Ontario Ministry of Health
and Long-term Care, Toronto. The objectives of the review
were to define in the province of Ontario 1) the geograph-
ic epidemiologic features of laboratory-confirmed blasto-
mycosis, 2) changes in the number of cases over time, and
3) demographic characteristics of infected persons. The
case report and study were approved by the research ethics
board of the Hospital for Sick Children, Toronto, Ontario.
Case Report
An 8-year-old, previously healthy Caucasian boy, was
brought to his family physician with a 2-month history of
neck pain and stiffness. The pain was not sufficient to
wake the child at night, but it prevented participation in
athletics. No history of trauma, fever, weakness, paresthe-
sias, weight loss, or change in bowel or bladder function
was noted. The initial diagnosis was muscular strain, and
rest and antiinflammatory medication was recommended.
When his symptoms did not improve, a cervical spine radi-
ograph showed a lytic lesion of the fifth cervical vertebra.
On hospital admission, physical examination was unre-
markable, with the exception of pain on palpation over the
posterior cervical spine. Laboratory results at admission
showed normal leukocyte count (8.0 × 109/L), differential
(polymorphs 4.48 × 109/L, eosinophils 0.08 × 109/L, lym-
phocytes 2.80 × 109/L, monocytes 0.56 × 109/L), elec-
trolytes, and renal function. Erythrocyte sedimentation rate
was mildly elevated at 38 mm/h. Computed tomographic
scan of the region showed a well-defined lytic lesion with
a “bubbly” appearance involving the posterior elements of
the C5 vertebral body. An incidental note was made of a
small, nonspecific lesion within the posterior upper lobe of
the right lung. Bone scintillography showed positive
uptake at C5. Magnetic resonance imaging (MRI) of the
cervical spine demonstrated an enhancing mass that
involved the posterior aspects of C5 plus an abnormal sig-
nal within the adjacent spinous processes. 
The patient underwent a C5 laminectomy and a C4 par-
tial hemilaminectomy. During dissection, a small amount
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Gram stain of the pus aspirate showed no organisms. Acal-
cofluor stain was positive for large, broad-based budding
yeast forms. Pathologic examination showed a destructive
lesion involving bone and soft tissues with both granulo-
matous and necrotizing suppurative components. The
numerous epithelioid granulomas contained Langhans
cells and foreign body giant cells, while the necrotizing
lesions contained neutrophilic and eosinophilic infiltrates.
Fungal elements highlighted with periodic acid–Schiff and
Gomori methenamine silver stains showed double-con-
toured cell walls surrounding a cytoplasmic mass and pro-
liferation in the form of broad-based buds. On the basis of
these features, a presumptive diagnosis of blastomycosis
was made. Subsequent fungal cultures grew a filamentous
dimorphic fungus identified as B. dermatitidis and con-
firmed by DNA probe (Accuprobe, Gen-Probe Inc., San
Diego, CA, USA).
The lung lesion in the right upper lobe could have also
been a focus of blastomycotic infection; however, bron-
choalveolar lavage or biopsies were not performed.
Intravenous amphotericin B, 30 mg every 24 h (1.0
mg/kg/d) was initiated. After 10 days, the dose was
reduced by 50% because of renal toxicity. On day 17 of
treatment, itraconazole (200 mg orally once per day) was
initiated and given concurrently with amphotericin B for 5
days, at which point amphotericin B was discontinued
because of laboratory evidence of renal failure. At the time
of discontinuation, 480 mg (16 mg/kg) had been given.
The patient’s clinical status improved, with resolution of
pain and a return of full cervical range of motion by time
of discharge.
Three weeks after completing a 6-month course of itra-
conazole, fever associated with vomiting and a sore throat
developed in the patient. Chest radiograph showed a con-
solidation in the upper lobe of the right lung. MRI of the
lung fields and cervical spine did not provide evidence of
recurrence of blastomycosis. Clarithromycin was initiated
and continued for 3 days with no improvement, at which
time itraconazole (200 mg orally once per day) was
resumed because blastomycosis could not be conclusively
ruled out. Antifungal therapy was continued for 6 months,
after which the patient was clinically healthy, and radi-
ographs of the cervical spine and chest were normal.
Field Epidemiologic Investigation of Case
The patient had visited a cottage on the lakeshore of an
island in the north health region of Ontario 5 months
before his hospitalization. Shortly after the owner pur-
chased the property, his dog and an adult male companion
both developed laboratory-confirmed, nonfatal blastomy-
cosis. Six months later, another adult male visitor devel-
oped a pneumonialike condition and was diagnosed with
laboratory-confirmed blastomycosis. A provincial epi-
demiologic team also determined that a dog belonging to a
previous owner of the property died of blastomycosis ≈2
years earlier. 
A year and a half after the initial human infection, the
cottage owner contacted the mycology laboratory at the
Ontario Ministry of Health and requested an environmen-
tal investigation. Atotal of 50 environmental samples were
taken from the property, including from a beaver lodge
(similar to those previously associated with blastomycosis
[8]) located underneath a boathouse. The samples were
taken ≈3 months after our patient’s presumed exposure.
Material from the samples was prepared in sterile physio-
logic saline and injected into 4 mice per sample, as out-
lined by Ajello and Weeks (9) for environmental isolation
of Histoplasma capsulatum. This technique had previous-
ly been used successfully to isolate B. dermatitidis (10).
No mice died of blastomycosis within 6 weeks (autopsy of
2 mice that died showed bacterial infection), and examina-
tion of the remaining 198 mice, euthanized after 6 weeks,
showed that livers, spleens, and lungs were clear of B. der-
matitidis by histopathology and by culture on Sabouraud
glucose agar with cycloheximide, chloramphenicol, and
gentamicin (CCG) and blood agar with CCG and 2.3% egg
albumin (11,12).
Laboratory-based Review of Blastomycosis 
in Ontario, 1994–2003
Methods
Cases were defined as all positive cultures of B. der-
matitidis isolated between November 1, 1994, and
December 31, 2003. CPHLprocesses primary cultures cul-
tivated from patient samples sent from referring facilities.
It also confirms the identity of cultures sent from referring
laboratories. Eleven public health laboratories are in
Ontario, and all of these laboratories, except the Thunder
Bay laboratory, refer all isolates of B. dermatitidis to the
CPHL for confirmation. Contact was made with the
Northwestern Ontario Health Unit in Kenora, Ontario, to
obtain records of confirmed cases of blastomycosis that
may not have been sent to CPHL. Some of these cases (and
their isolates) are referred to Winnipeg rather than south-
ern Ontario, and some isolates are identified only at the
Thunder Bay laboratory. By contacting the specific region
that does not refer all cases to the CPHL, a high level of
case capturing is ensured. Information obtained regarding
each infected person included date of birth, sex, and loca-
tion of diagnosis. Ontario is divided into 7 health regions
(Toronto, southwest, central-south, central-west, central-
east, east, and north). Incidence per 100,000 population per
year was derived by using population data from Statistics
Canada (B. Ball, pers. comm.). 
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A total of 309 culture-positive cases of blastomycosis
were identified in Ontario during the study period. Each of
Ontario’s 7 health regions had cases identified (Figure 1);
61% (n = 188) of the cases were diagnosed in the north
region, and 21% (n = 66) were diagnosed in the Toronto
region. Of the north region cases, 89% (n = 167) were from
the Northwestern Health Unit’s district, which includes
Kenora. 
The mean number of cases diagnosed per year was
33.7; the fewest number of cases was in 1995 (n = 10), and
the greatest number was in 2002 (n = 71) (Figure 2). The
number of cases has increased in recent years; 57% (n =
175) were reported in the 3-year period from 2001 to 2003.
While cases were diagnosed year-round, 59% (n = 181)
occurred in the fall and winter months, from October to
March (Figure 3). The age of patients with positive isolates
was recorded for 92% (n = 283) of cases; ≈60% were
30–59 years of age (range 6 months to 83 years) (Figure 4).
The sex of the affected person was available in 97% (n =
301); 65% (n = 196) were male, and 35% (n = 105) were
female. The incidence ranged from a low in the south-cen-
tral Ontario region of 0.02 cases per year per 100,000 pop-
ulation to a high in the north Ontario region of 2.44 cases
per year per 100,000 population (Figure 1). Age-specific
incidence rates are shown in Figure 4.
Discussion
Case Report
Blastomycosis is a rare but potentially fatal infection
caused by the thermally dimorphic fungus B. dermatitidis.
It is presumed to be a soil organism, and factors that favor
it include moisture, high content of organic material, acidic
pH, and exposure to animal excreta (8,13). Primary infec-
tion generally follows inhalation of conidia, asexual fungal
spores that are shed at maturity. Blastomycosis often has
nonspecific initial symptoms: fever, malaise, myalgias,
weight loss, cough, and pleuritic chest pain (14). The
course of illness may be either acute or chronic. While any
organ may be involved, lung involvement is most com-
mon, manifesting either as a lobar infiltrate resembling a
bacterial pneumonia, a miliary infiltration similar to tuber-
culosis, or as a large mass that is initially suspected of
being a bronchogenic carcinoma. The second most com-
mon type of disease is cutaneous. Less common clinical
syndromes involve bone, the genitourinary system, or the
central nervous system (CNS). In contrast to most other
invasive fungal infections, blastomycosis most commonly
affects immunocompetent persons.
Children make up 2%–11% of cases in previous studies
(15,16). Published case reports and case series of pediatric
blastomycosis highlight the potential for pulmonary, bone,
and CNS disease, as well as neonatal disease and intrauter-
ine transmission (6,15–20). In our review, 13% of patients
were <19 years of age. 
Recent guidelines from the National Institute of Allergy
and Infectious Diseases Mycoses Study Group and the
Infectious Diseases Society of America suggest that life-
threatening pulmonary or disseminated non-CNS disease,
any CNS disease, and disease in the immunocompromised
host be treated with amphotericin B to complete a total
dose of 1.5–2.5 g (21–36 mg/kg for a 70-kg person). For
patients who do not tolerate amphotericin, it can be used
initially until the condition has stabilized at which point
itraconazole (for non-CNS disease) or high-dose flucona-
zole (for CNS disease) can be used as stepdown therapy
(21). Mild-to-moderate pulmonary and disseminated non-
CNS disease can be treated by itraconazole from onset.
Duration of therapy with itraconazole should be >6
months, except in the case of osteomyelitis, which has a
higher rate of relapse (22). Bone disease should be treated
with >1 year of antifungal medications. Relapse is a recog-
nized outcome in blastomycosis and may occur after any
treatment regimen (22–24). Therefore, in our case, given
the vertebral involvement, 1 year of itraconazole therapy
was warranted. 
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Figure 1. Incidence of blastomycosis by Ontario health region.
Figure 2. Blastomycosis diagnosed by year, Ontario, 1994–2003.Epidemiologic Report
B. dermatitidis is endemic in the United States around
the Mississippi and Ohio River basins, Midwestern states,
Canadian provinces bordering the Great Lakes, and small
areas bordering the St. Lawrence River (25). Ontario has
an area >1 million km2 and can be divided into 3 natural
regions: the rolling uplands of the Canadian shield across
the center of the province, the Hudson Bay lowlands to the
north, and the Great Lakes and St. Lawrence lowlands to
the south. The northwestern portion of the province is
largely forested and dotted with lakes and rivers. 
While the epidemiologic investigation described in our
case failed to yield positive environmental cultures, the
link between beaver dwellings and blastomycosis has pre-
viously been suggested (8). Other outbreaks have been
reported in association with construction of a log cabin
(26), an urban construction site (27), outdoor riverside
camping (28), raccoon hunting (29), and travel to a specif-
ic small island (30).
Blastomycosis was a reportable disease in Ontario until
1989 (31). Most Canadian cases have been reported from
Ontario and Manitoba (3,11,31–35). From 1981 to 1989,
before the removal of blastomycosis from the list of
reportable diseases, 16 cases were recorded in Ontario, a
mean of 1.8 cases per year (31). The current review sug-
gests that blastomycosis is more common than previously
thought, with a mean of 33.7 cases diagnosed per year in
the 10-year study period. Hyperendemicity in the region
surrounding Kenora, Ontario, has recently been reported
(35), with an estimated annual incidence rate of 117.2
cases per 100,000 population (35). This amount exceeds
the next highest rate reported in North America of 100
cases per 100,000 population in the Eagle River area in
Vilas County, Wisconsin (36). An increase was noted in the
number of cases of blastomycosis identified per year since
the late 1990s (Figure 2). Increased awareness in Kenora
because of an education campaign aimed at physicians
after a fatal case of blastomycosis in 1998 may account in
part for the increased number of recognized cases. Our
identification of 309 laboratory-confirmed cases of blasto-
mycosis represents the largest group of confirmed cases
and substantially increases the total number of known
cases in both Ontario and Canada. 
During the study period, 66 cases were diagnosed in
Toronto. While blastomycosis has previously been report-
ed in persons who have not traveled outside of the greater
Toronto area (5,6), we could not confirm where infection
was acquired in the 66 Toronto patients. The major limita-
tion of this study is that the geographic data are based on
location of diagnosis, which may not be reflective of loca-
tion of infection. Infection may occur in rural regions that
are frequent destinations of travel for many Ontario resi-
dents.
The preponderance (58%, p = 0.0005) of diagnoses in
fall and winter noted in our study has previously been
reported (35). The incubation period for symptomatic blas-
tomycosis is 1–3 months (13,37). Therefore, infection is
thought to mainly occur in summer and fall, when persons
spend time outdoors, snow cover is minimal, and rainfall is
high, thereby increasing exposure to this soil organism
(8,13).
Early Canadian studies (2,33) found most (85%–88%)
cases to be in males, and early studies from the United
States suggested a male-to-female ratio of 4:1–15:1 (38).
More recent studies in Canada (31,35) and the United
States (39) suggest that the male sex predominance is not
as large. In our study, 65.1% of patients were male, similar
to the proportion noted by Crampton et al. (32). 
Previous studies have suggested increased rates of
infection for both African Americans (40) and Aboriginals
(35). Whether this finding is related to genetic or exposure
factors is unclear. Given the retrospective nature of this
laboratory review, we could not determine the ethnicity of
the cases. Future work must identify high-risk groups
within the population so that targeted prevention efforts
may be put in place.
Despite being the largest series of cases of blastomyco-
sis reported in Ontario, our data may underestimate the
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Figure 3. Blastomycosis diagnosed by season, Ontario,
1994–2003.
Figure 4. Number of blastomycosis cases and incidence rates by
age, Ontario, 1994–2003.true incidence of disease in the province. The number of
cases diagnosed in northwestern Ontario increased after an
education campaign. To our knowledge, no similar cam-
paign has been carried out elsewhere in the province, and
therefore the diagnosis is likely often missed. Some sam-
ples may have been only identified at a regional laborato-
ry and not counted among our data. Because of the
geographic proximity, patients in northwestern Ontario are
often transferred to Winnipeg, Manitoba, rather than to an
Ontario tertiary centre for investigation and treatment.
Additionally, persons from outside the province who are
infected may be diagnosed in their home provinces. As a
result, some cases of blastomycosis acquired in Ontario
may be diagnosed in Manitoba or elsewhere and therefore
are not included in our data.
Conclusion
The understanding of the natural distribution of blasto-
mycosis and other mycoses endemic in Ontario (such as
histoplasmosis) is minimal. This study is the first to
describe the Ontario-wide incidence of blastomycosis and
to provide incidence rates in each of the 7 provincial health
regions. Clinicians practicing throughout the province and
country may encounter persons infected with this organism
and need to be familiar with its varied clinical signs and
symptoms and be aware of regions where disease is
endemic or hyperendemic. Our data suggest that the num-
ber of diagnoses of blastomycosis has increased over sev-
eral years. However, the disease likely remains
underrecognized. As delay to diagnosis can contribute to
illness and death, clinicians should consider blastomycosis
in their differential diagnoses of lung, skin, and bone dis-
eases, particularly if the patient does not respond to con-
ventional antimicrobial drug therapy. The lack of rapid and
effective diagnostic tools contributes to the underrecogni-
tion of blastomycosis. Advances in molecular diagnosis of
B. dermatitidis (39), particularly in regions identified as
higher risk, hold the potential for improving case detection
and decreasing delay to diagnosis. 
Infection by B. dermatitidis is more common than was
thought before its removal from the list of reportable dis-
eases in Ontario in 1989. Our group advocates strongly for
returning blastomycosis to the reportable diseases list in
this province. Travel history must be included in the
reporting of blastomycosis. While identifying the point of
infection in well-traveled individuals may be impossible, a
specific or negative travel history would make a valuable
contribution to understanding where blastomycosis is con-
tracted in Ontario. Such reporting would facilitate tracking
cases and clinical education regarding this potentially fatal
invasive fungal infection.
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